Organon & Co. (OGN) Competitors

Organon & Co. (NYSE:OGN) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Is OGN or BBIO more profitable?

Organon & Co. has a net margin of 11.15% compared to BridgeBio Pharma's net margin of -329.25%. Organon & Co.'s return on equity of 163.88% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	11.15%	163.88%	6.99%
BridgeBio Pharma	-329.25%	N/A	-85.69%

Do insiders & institutionals believe in OGN or BBIO?

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 2.0% of Organon & Co. shares are held by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has more risk and volatility, OGN or BBIO?

Organon & Co. has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.

Do analysts prefer OGN or BBIO?

Organon & Co. currently has a consensus price target of $18.00, indicating a potential upside of 99.76%. BridgeBio Pharma has a consensus price target of $61.35, indicating a potential upside of 22.24%. Given Organon & Co.'s higher possible upside, research analysts plainly believe Organon & Co. is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
BridgeBio Pharma	0 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher earnings & valuation, OGN or BBIO?

Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.40B	0.37	$864M	$2.69	3.35
BridgeBio Pharma	$221.90M	43.24	-$535.76M	-$4.09	-12.27

Does the media favor OGN or BBIO?

In the previous week, BridgeBio Pharma had 11 more articles in the media than Organon & Co.. MarketBeat recorded 16 mentions for BridgeBio Pharma and 5 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.59 beat BridgeBio Pharma's score of 0.88 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Organon & Co. beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.